205 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
18 May 18
GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting
2:40pm
to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women … with stress urinary incontinence (SUI). The presentation, entitled Oral Enobosarm Shows Promising Activity in Post-Menopausal Women with Stress Urinary
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
30 Apr 13
Other Events
12:00am
), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer.
“We know from prior studies that women … will randomize twenty (20) postmenopausal women with estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormone therapy
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
14 Aug 18
GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results
7:30am
women with stress urinary incontinence (SUI),” said Robert J. Wills, Ph.D., Executive Chairman of GTx. “Due to overwhelming interest from women wanting … the efficacy and safety of enobosarm administered orally in post-menopausal women with SUI compared to placebo. More information about the ASTRID (Assessing
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
15 May 18
GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
7:15am
additional positive results in a subset of women with both SUI and urge incontinence,” said Robert J. Wills, Ph.D., Executive Chairman of GTx. “We look … forward to presenting additional data from our open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
21 Sep 18
GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence
8:30am
Exhibit 99.1
GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence
MEMPHIS … clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve statistical
8-K
EX-99.1
9kb szyn0j
2 Jun 14
Other Events
12:00am
8-K
EX-99.1
sag988sq51 umfx
3 May 13
GTx PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
8n38kd
10 Nov 14
GTx PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS
12:00am
8-K
EX-99.1
358re oa2n2f6oj1
21 Jun 10
GTx Announces Ostarine Increased Lean Body Mass and Leg Press Strength in Head to Head Clinical Study
12:00am
8-K
EX-99.1
840k tq34rwekw06g
22 Oct 18
GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
7:30am
8-K
EX-99.1
m2o23efe6gw3vute
20 Jul 06
Other Events
12:00am
8-K
EX-99.1
9yq zh70bnguws9f
2 Nov 06
GTX, Inc. Reports Third Quarter 2006 Financial Results
12:00am